Clinical trial NCT04091126: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Official title: A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Multiple Myeloma
Keywords: Bortezomib
Lenalidomide
dexamethasone
VRd
Belantamab mafodotin
Newly diagnosed multiple myeloma
RP3D
DREAMM 9
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2019-09-16
Enrollment: 118
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The study will evaluate different doses/dose schedules of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone, (VRd) in up to 8 cohorts and will determine the Recommended Phase 3 dose (RP3D).
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantamab mafodotin will be administered in combination with VRd every 3 weeks (Q3W), every 6 weeks (Q6W), or every 9 weeks (Q9W) to Cycle 8, and then in combination with Rd every 4 weeks (Q4W), every 8 weeks (Q8W), or every 12 weeks (Q12W) thereafter. Participants will complete an End of Treatment (EOT) visit at the point of study treatment discontinuation, followed by a Safety Follow-up visit 70 days after EOT.


Eligibility criteria: Inclusion Criteria:

* Participant must be over 18 years of age inclusive, at the time of signing the informed consent.
* Diagnosis of multiple myeloma with a requirement for treatment as documented per international myeloma working group (IMWG) criteria.
* Must have at least one aspect of measurable disease, defined as one of the following:
* Urine M-protein excretion \>=200 mg/24 hours (\>=0.2 gram \[g\]/24 hours), or
* Serum M-protein concentration \>=0.5 grams per deciliter (g/dL) (\>=5.0 gram per liter \[g/L\]), or
* Serum free light chain (FLC) assay: involved FLC level \>=10 milligrams per deciliter (mg/dL) (\>=100 milligram per liter \[mg/L\]) and an abnormal serum free light chain ratio (\<0.26 or \>1.65).
* Not a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to presence of significant comorbid condition(s), such as cardiac, pulmonary or other major organ dysfunction that are likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation, as judged by the investigator.
* Eastern cooperative oncology group (ECOG) status of 0-2
* Adequate organ system functions as defined by the laboratory assessments listed as following: Absolute neutrophil count (ANC) \>=1.5 x 10\^9/L; Hemoglobin \>=8.0 g/dL; Platelets \>=75 x 10\^9/L; Total bilirubin \<=1.5 x upper limit of normal (ULN); (Isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%); Alanine aminotransferase (ALT) \<=2.5 x ULN; eGFR \>=30 mL/minute/1.73 meter\^2; Urine Dipstick for protein OR Albumin/creatinine ratio (from spot urine)- Negative/trace (if \>=1 plus only eligible if confirmed \<=500 mg/gram (56 mg/millimoles \[mmol\]) by albumin/creatinine ratio (spot urine from first void); Left Ventricular Ejection Fraction (LVEF) by echocardiogram (ECHO) of \>=35% participants with low LVEF (per institutional standards), consider referring to cardiology per local standards of care.
* Sex and Contraception/Barrier Requirements (Female):
* Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
* Is NOT a woman of childbearing potential (WOCBP) or Due to lenalidomide being a thalidomide analogue with risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, and bortezomib having the potential to cause fetal harm, WOCBP participants will be eligible if they commit to either: abstain continuously from heterosexual sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR to use birth control as follows: Two methods of reliable birth control (one method that is highly effective and one additional effective (barrier) method), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use one method of reliable birth control that is highly effective for a further 3 months following discontinuation of belantamab mafodotin, or a further 6 months following discontinuation of bortezomib, whichever is longer. WOCBP must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during treatment, during dose interruptions and for 28-days following the last dose of lenalidomide, 4 months following discontinuation of belantamab mafodotin treatment or 7-months following the last dose of bortezomib, whichever is longer. Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing the start of lenalidomide therapy.

The participant should not receive lenalidomide until the investigator has verified that the results of these pregnancy tests are negative. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

* Sex and Contraception/Barrier Requirements (Male):
* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* Male participants are eligible to participate if they agree to the following from the time of first dose of study treatment until 28-days after the last dose of lenalidomide, 4-months after the last dose of bortezomib, or 6 months after the last dose of belantamab mafodotin, whichever is longer, to allow for clearance of any altered sperm: Refrain from donating sperm - Plus either: - Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a WOCBP. Male participants should also use a condom when having sexual intercourse with pregnant females.
* Capable of giving signed informed consent.

Exclusion Criteria:

* Smoldering multiple myeloma (SMM).
* Prior systemic therapy for multiple myeloma, or SMM. NOTE: An emergency course of steroids (defined as no greater than 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days (that is, a total of 160 mg) is permitted. NOTE: Focal palliative radiation is permitted prior to enrollment, provided that it occurred at least 2 weeks prior to the first dose of study drug, that the participant has recovered from radiation-related toxicities, and that the participant did not require corticosteroids for radiation-induced adverse events.
* Participant is eligible for high dose chemotherapy with ASCT, as determined by a frailty score of 0 as assessed by the IMWG frailty index.
* Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) Version 5.
* Major surgery within 4 weeks prior to the first dose of study drug.
* Presence of active renal condition (infection, requirement for dialysis or any other significant condition that could affect participant's safety). Participants with isolated proteinuria resulting from multiple myeloma (MM) are eligible, provided they fulfil criteria.
* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.
* Evidence of active mucosal or internal bleeding uncontrolled by local therapy and not explained by reversible coagulopathy.
* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the Investigator's assessment).
* Participants with previous or concurrent malignancies other than multiple myeloma are excluded. Exceptions are surgically treated cervical carcinoma in situ, or any other malignancy that has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. Note: Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction.
* Evidence of cardiovascular risk including any of following: Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities including second degree (Mobitz Type II) or third degree atrioventricular (AV) block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening.; Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; Uncontrolled hypertension.
* Active infection requiring treatment.
* Known human immunodeficiency virus (HIV) infection.
* Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb), at Screening or within 3 months prior to first dose of study treatment.
* Positive hepatitis C antibody test result.
* Current corneal epithelial disease except for mild punctate keratopathy. Note: Participants with mild punctate keratopathy are allowed.
* Intolerance or contraindications to anti-viral prophylaxis.
* Unable to tolerate antithrombotic prophylaxis.
* AL amyloidosis (light chain amyloidosis), active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes (POEMS) syndrome or active plasma cell leukemia at the time of screening.
* Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma.
* Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
* Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.
* Plasmapheresis within 7 days prior to the first dose of study drug.

Primary outcomes:
measure: Number of participants with dose-limiting toxicities (DLTs)
timeFrame: Treatment cycle 1 to 3 (each cycle of 21 days)
measure: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
timeFrame: Up to an average of 54 months
Secondary outcomes:
measure: Lenalidomide relative dose intensity (RDI ) of treatment with belantamab mafodotin in combination with VRd
timeFrame: 4 treatment cycles (each cycle of 21 days)
measure: Bortezomib RDI of treatment with belantamab mafodotin in combination with VRd
timeFrame: 4 treatment cycles (each cycle of 21 days)
measure: Cumulative administered dose of belantamab mafodotin treatment in combination with VRd
timeFrame: 4 treatment cycles (each cycle of 21 days)
measure: Maximum plasma concentration (Cmax) of belantamab mafodotin
timeFrame: Up to an average of 52 months
measure: Cmax of microtubule inhibitor monomethyl auristatin-F with a cysteine linker (cys-mcMMAF)
timeFrame: Up to an average of 52 months
measure: Area under the concentration time curve (AUC) of belantamab mafodotin
timeFrame: Up to an average of 52 months
measure: AUC of cys-mcMMAF
timeFrame: Up to an average of 52 months
measure: Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin
timeFrame: Up to an average of 52 months
measure: Titers of ADAs against belantamab mafodotin
timeFrame: Up to an average of 52 months
measure: Overall Response Rate (ORR)
timeFrame: Up to 52 months
measure: Complete Response Rate (CRR)
timeFrame: Up to 52 months
measure: Rate of Very Good Partial Response (VGPR) or better
timeFrame: Up to 52 months
Other outcomes:
Locations:
city: Westwood
country: United States
facility: GSK Investigational Site
state: Kansas
city: Charlotte
country: United States
facility: GSK Investigational Site
state: North Carolina
city: Madison
country: United States
facility: GSK Investigational Site
state: Wisconsin
city: Newcastle
country: Australia
facility: GSK Investigational Site
state: New South Wales
city: Clayton
country: Australia
facility: GSK Investigational Site
state: Victoria
city: Fitzroy
country: Australia
facility: GSK Investigational Site
state: Victoria
city: Edmonton
country: Canada
facility: GSK Investigational Site
state: Alberta
city: London
country: Canada
facility: GSK Investigational Site
state: Ontario
city: Poitiers
country: France
facility: GSK Investigational Site
city: Dresden
country: Germany
facility: GSK Investigational Site
city: Hamburg
country: Germany
facility: GSK Investigational Site
city: Schwerin
country: Germany
facility: GSK Investigational Site
city: Tuebingen
country: Germany
facility: GSK Investigational Site
city: Bologna
country: Italy
facility: GSK Investigational Site
city: Meldola FC
country: Italy
facility: GSK Investigational Site
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
city: Lublin
country: Poland
facility: GSK Investigational Site
city: Poznan
country: Poland
facility: GSK Investigational Site
city: Badalona
country: Spain
facility: GSK Investigational Site
city: Barcelona
country: Spain
facility: GSK Investigational Site
city: Madrid
country: Spain
facility: GSK Investigational Site
city: Malaga
country: Spain
facility: GSK Investigational Site
city: PamplonaNavarra
country: Spain
facility: GSK Investigational Site
city: Pozuelo De AlarcOn Madr
country: Spain
facility: GSK Investigational Site
city: Santander
country: Spain
facility: GSK Investigational Site
city: Leicester
country: United Kingdom
facility: GSK Investigational Site
city: Oxford
country: United Kingdom
facility: GSK Investigational Site
city: Southampton
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: